AN2 Therapeutics (ANTX) Preferred Stock Liabilities (2021)
AN2 Therapeutics (ANTX) reported Preferred Stock Liabilities of $109.3 million for Q4 2021, up 1.79% quarter-over-quarter from $107.4 million in Q3 2021.
AN2 Therapeutics (ANTX) Preferred Stock Liabilities (2021) Analysis & Trends
AN2 Therapeutics (ANTX) has 1 years of Preferred Stock Liabilities data on file, last reported at $109.3 million in Q4 2021.
- Preferred Stock Liabilities for Q4 2021 came in at $109.3 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2021 was $109.3 million (changed N/A YoY), and the FY2021 annual result was $109.3 million, changed N/A from the prior year.
- Preferred Stock Liabilities grew to $109.3 million in Q4 2021 per ANTX's latest filing, from $107.4 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $109.3 million in Q4 2021 and troughed at $103.6 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | AN2 Therapeutics | 161.95 Mn | 161.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 109.32 Mn |
| Sep 30, 2021 | 107.39 Mn |
| Jun 30, 2021 | 105.47 Mn |
| Mar 31, 2021 | 103.57 Mn |